BPG is committed to discovery and dissemination of knowledge
Cited by in F6Publishing
For: Gou W, Fu Y, Yue L, Chen GD, Cai X, Shuai M, Xu F, Yi X, Chen H, Zhu Y, Xiao ML, Jiang Z, Miao Z, Xiao C, Shen B, Wu X, Zhao H, Ling W, Wang J, Chen YM, Guo T, Zheng JS. Gut microbiota, inflammation, and molecular signatures of host response to infection. J Genet Genomics 2021:S1673-8527(21)00094-1. [PMID: 34257044 DOI: 10.1016/j.jgg.2021.04.002] [Cited by in Crossref: 1] [Cited by in F6Publishing: 22] [Article Influence: 1.0] [Reference Citation Analysis]
Number Citing Articles
1 Malik JA, Ahmed S, Yaseen Z, Alanazi M, Alharby TN, Alshammari HA, Anwar S. Association of SARS-CoV-2 and Polypharmacy with Gut–Lung Axis: From Pathogenesis to Treatment. ACS Omega. [DOI: 10.1021/acsomega.2c02524] [Reference Citation Analysis]
2 Enichen E, Harvey C, Demmig-adams B. COVID-19 Spotlights Connections between Disease and Multiple Lifestyle Factors. American Journal of Lifestyle Medicine. [DOI: 10.1177/15598276221123005] [Reference Citation Analysis]
3 Golla R, Vuyyuru SK, Kante B, Kedia S, Ahuja V. Disorders of gut-brain interaction in post-acute COVID-19 syndrome. Postgrad Med J 2022:postgradmedj-2022-141749. [PMID: 35777934 DOI: 10.1136/pmj-2022-141749] [Reference Citation Analysis]
4 Zhang G, Cui X, Zhang L, Liu G, Zhu X, Shangguan J, Zhang W, Zheng Y, Zhang H, Tang J, Zhang J. Uncovering the genetic links of SARS-CoV-2 infections on heart failure co-morbidity by a systems biology approach. ESC Heart Fail 2022. [PMID: 35727093 DOI: 10.1002/ehf2.14003] [Reference Citation Analysis]
5 Aggarwal V, Sunder S, Verma SR. Disease-associated dysbiosis and potential therapeutic role of Akkermansia muciniphila, a mucus degrading bacteria of gut microbiome. Folia Microbiol (Praha) 2022. [PMID: 35596115 DOI: 10.1007/s12223-022-00973-6] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
6 Melo-González F, Sepúlveda-Alfaro J, Schultz BM, Suazo ID, Boone DL, Kalergis AM, Bueno SM. Distal Consequences of Mucosal Infections in Intestinal and Lung Inflammation. Front Immunol 2022;13:877533. [PMID: 35572549 DOI: 10.3389/fimmu.2022.877533] [Reference Citation Analysis]
7 Takáčová M, Bomba A, Tóthová C, Micháľová A, Turňa H. Any Future for Faecal Microbiota Transplantation as a Novel Strategy for Gut Microbiota Modulation in Human and Veterinary Medicine? Life 2022;12:723. [DOI: 10.3390/life12050723] [Reference Citation Analysis]
8 Xu L, Ho C, Liu Y, Wu Z, Zhang X. Potential Application of Tea Polyphenols to the Prevention of COVID-19 Infection: Based on the Gut-Lung Axis. Front Nutr 2022;9:899842. [DOI: 10.3389/fnut.2022.899842] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 2.0] [Reference Citation Analysis]
9 Ghazanfar H, Kandhi S, Shin D, Muthumanickam A, Gurjar H, Qureshi ZA, Shaban M, Farag M, Haider A, Budhathoki P, Bhatt T, Ghazanfar A, Jyala A, Patel H. Impact of COVID-19 on the Gastrointestinal Tract: A Clinical Review. Cureus. [DOI: 10.7759/cureus.23333] [Cited by in F6Publishing: 1] [Reference Citation Analysis]
10 Xiong Z, Peng K, Song S, Zhu Y, Gu J, Huang C, Li X. Cerebral Intraparenchymal Hemorrhage Changes Patients’ Gut Bacteria Composition and Function. Front Cell Infect Microbiol 2022;12:829491. [DOI: 10.3389/fcimb.2022.829491] [Cited by in F6Publishing: 1] [Reference Citation Analysis]
11 Yoshino A, Nakamura Y, Hashiguchi S, Ishida S, Mano R, Nakamura S, Kita R, Seto M, Takata T, Ishikura H, Kondo S. The Association between the Oral-Gut Axis and the Outcomes of Severe COVID-19 Patients Receiving Extracorporeal Membrane Oxygenation: A Case-Control Study. J Clin Med 2022;11:1167. [PMID: 35268256 DOI: 10.3390/jcm11051167] [Reference Citation Analysis]
12 Wang R, Deng Y, Zhang Y, Li X, Sun L, Deng Q, Liu Y, Gooneratne R, Li J. Modulation of Intestinal Barrier, Inflammatory Response, and Gut Microbiota by Pediococcus pentosaceus zy-B Alleviates Vibrio parahaemolyticus Infection in C57BL/6J Mice. J Agric Food Chem 2022. [PMID: 35107008 DOI: 10.1021/acs.jafc.1c07450] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 2.0] [Reference Citation Analysis]
13 Merra G, Capacci A, Cenname G, Esposito E, Dri M, Di Renzo L, Marchetti M. The “Microbiome”: A Protagonist in COVID-19 Era. Microorganisms 2022;10:296. [DOI: 10.3390/microorganisms10020296] [Reference Citation Analysis]
14 Xavier-Santos D, Padilha M, Fabiano GA, Vinderola G, Gomes Cruz A, Sivieri K, Costa Antunes AE. Evidences and perspectives of the use of probiotics, prebiotics, synbiotics, and postbiotics as adjuvants for prevention and treatment of COVID-19: A bibliometric analysis and systematic review. Trends Food Sci Technol 2022;120:174-92. [PMID: 35002079 DOI: 10.1016/j.tifs.2021.12.033] [Cited by in Crossref: 14] [Cited by in F6Publishing: 10] [Article Influence: 14.0] [Reference Citation Analysis]
15 Szychowiak P, Villageois-Tran K, Patrier J, Timsit JF, Ruppé É. The role of the microbiota in the management of intensive care patients. Ann Intensive Care 2022;12:3. [PMID: 34985651 DOI: 10.1186/s13613-021-00976-5] [Cited by in Crossref: 6] [Cited by in F6Publishing: 3] [Article Influence: 6.0] [Reference Citation Analysis]
16 Ventero MP, Moreno-Perez O, Molina-Pardines C, Paytuví-Gallart A, Boix V, Escribano I, Galan I, González-delaAleja P, López-Pérez M, Sánchez-Martínez R, Merino E, Rodríguez JC. Nasopharyngeal Microbiota as an early severity biomarker in COVID-19 hospitalised patients: a retrospective cohort study in a Mediterranean area. J Infect 2021:S0163-4453(21)00647-2. [PMID: 34963638 DOI: 10.1016/j.jinf.2021.12.030] [Cited by in Crossref: 2] [Cited by in F6Publishing: 1] [Article Influence: 2.0] [Reference Citation Analysis]
17 Kageyama Y, Nishizaki Y, Aida K, Yayama K, Ebisui T, Akiyama T, Nakamura T. Lactobacillus plantarum induces innate cytokine responses that potentially provide a protective benefit against COVID-19: A single-arm, double-blind, prospective trial combined with an in vitro cytokine response assay. Exp Ther Med 2022;23:20. [PMID: 34815772 DOI: 10.3892/etm.2021.10942] [Cited by in F6Publishing: 4] [Reference Citation Analysis]
18 Tan HW, Xu YM, Lau ATY. Human bronchial-pulmonary proteomics in coronavirus disease 2019 (COVID-19) pandemic: applications and implications. Expert Rev Proteomics 2021;18:925-38. [PMID: 34812694 DOI: 10.1080/14789450.2021.2010549] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
19 Sarkar A, Harty S, Moeller AH, Klein SL, Erdman SE, Friston KJ, Carmody RN. The gut microbiome as a biomarker of differential susceptibility to SARS-CoV-2. Trends Mol Med 2021;27:1115-34. [PMID: 34756546 DOI: 10.1016/j.molmed.2021.09.009] [Cited by in F6Publishing: 3] [Reference Citation Analysis]
20 Shenoy S. Gut microbiome, Vitamin D, ACE2 interactions are critical factors in immune-senescence and inflammaging: key for vaccine response and severity of COVID-19 infection. Inflamm Res 2021. [PMID: 34738147 DOI: 10.1007/s00011-021-01510-w] [Cited by in F6Publishing: 1] [Reference Citation Analysis]
21 Al Kassaa I, El Omari S, Abbas N, Papon N, Drider D, Kassem II, Osman M. High association of COVID-19 severity with poor gut health score in Lebanese patients. PLoS One 2021;16:e0258913. [PMID: 34673813 DOI: 10.1371/journal.pone.0258913] [Cited by in F6Publishing: 1] [Reference Citation Analysis]
22 Hilpert K. Is the Gut Microbiome a Target for Adjuvant Treatment of COVID-19? Biologics 2021;1:285-99. [DOI: 10.3390/biologics1030017] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]